- ICH GCP
- Amerikanska kliniska prövningsregistret
- Klinisk prövning NCT02591732
A Nationwide Registry Study of Patients With Nonvalvular Atrial Fibrillation Initiating Oral Anticoagulation Therapies In The Early Period Following Apixaban Marketing In Denmark
A Nation-wide Registry Study of Patients With Non-valvular Atrial Fibrillation Initiating Anticoagulation Therapies in the Early Period Follow Apixaban Marketing in Denmark: Patient Characteristics, Treatment Patterns, and Early Bleeding Events
The purpose of this study is to describe the characteristics of patients treated with different OATs and whether these characteristics differ between treatments.
Furthermore to describe persistence to each OAT and risk of bleeding after initiating each OAT.
Studieöversikt
Status
Betingelser
Studietyp
Inskrivning (Faktisk)
Kontakter och platser
Studieorter
-
-
-
Hellerup, Danmark, 2900
- Local Institution
-
-
Deltagandekriterier
Urvalskriterier
Åldrar som är berättigade till studier
Tar emot friska volontärer
Kön som är behöriga för studier
Testmetod
Studera befolkning
Beskrivning
Inclusion Criteria:
The study population will consist of all patients in Denmark who meet the following criteria:
- Adult (≥18 years) at time of anticoagulant initiation
- Diagnosed with atrial fibrillation without recorded valvular disease
- Initiated a new OAT during the study period (January 1, 2011 and December 31, 2014).
- For the identification of NVAF cases, the appearance at least one hospital discharge diagnosis of AF will be searched in the databases.
Exclusion Criteria:
- Patients with prosthetic heart valves , rheumatic mitral or aortic valve disorders, and mitral aortic stenosis will be excluded
Studieplan
Hur är studien utformad?
Designdetaljer
Kohorter och interventioner
Grupp / Kohort |
---|
Patient behandlad med Apixaban
|
Patient behandlad med Rivaroxaban
|
Patient behandlad med Dabigatran
|
Patient behandlad med vitamin K-antagonister
|
Vad mäter studien?
Primära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
---|---|---|
The sociodemographic characteristics of all patients with nonvalvular atrial fibrillation (NVAF) who initiated an OAT based on data available in Danish National Patient Registry
Tidsram: Approximately 4 years
|
Sociodemographic characteristics: Age,sex, ethnicity, region of residence, education, income and employment status
|
Approximately 4 years
|
Clinical characteristics of all patients with NVAF who initiated an Oral anticoagulant therapy (OAT) based on data available in Danish National Patient Registry
Tidsram: Approximately 4 years
|
Clinical characteristics: Myocardial infarction, Stroke, Thromboembolism, Hypertension, Peripheral artery disease, Congestive cardiac failure
|
Approximately 4 years
|
Previous Oral anticoagulant therapy of all patients with NVAF who initiated an OAT based on data available in Danish National Patient Registry
Tidsram: Approximately 4 years
|
Oral anticoagulant: Apixaban, Dabigatran, Rivaroxaban and Vitamin K antagonist
|
Approximately 4 years
|
Concomitant medications of all patients with NVAF who initiated an OAT based on data available in Danish National Patient Registry
Tidsram: Approximately 4 years
|
Concomitant medication Drug classes: Anti-arrhythmic agents, Antidiabetic agents, Antihypertensive agents, Proton pump inhibitors
|
Approximately 4 years
|
Sekundära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
---|---|---|
Persistence to each OAT after initiation as monotherapy
Tidsram: Approximately 4 years
|
Persistence will be defined as treatment discontinuation and will be measured by estimating the following: Discontinuation - the absence of any delivery of this product and of any other anticoagulation therapy of interest for 30 days. The date of discontinuation the OAT will be determined according to predefined algorithms to calculate treatment duration in the national prescription registry. Sensitivity analysis including a 30 and 60 day grace period will be performed to take into account incomplete adherence to treatment and dose modifications |
Approximately 4 years
|
Persistence between apixaban and other OAT
Tidsram: Approximately 4 years
|
Oral anticoagulant: Dabigatran, Rivaroxaban and Vitamin K antagonist
|
Approximately 4 years
|
Clinically relevant bleeding events after initiating an OAT as monotherapy
Tidsram: Approximately 4 years
|
Approximately 4 years
|
|
Bleeding events requiring hospitalization in patients treated with apixaban
Tidsram: Approximately 4 years
|
Approximately 4 years
|
|
Bleeding events requiring out-patient care in patients treated with apixaban
Tidsram: Approximately 4 years
|
Approximately 4 years
|
|
Bleeding events requiring hospitalization in patients treated with rivaroxaban
Tidsram: Approximately 4 years
|
Approximately 4 years
|
|
Bleeding events requiring out-patient care in patients treated with rivaroxaban
Tidsram: Approximately 4 years
|
Approximately 4 years
|
Samarbetspartners och utredare
Sponsor
Samarbetspartners
Studieavstämningsdatum
Studera stora datum
Studiestart
Primärt slutförande (Faktisk)
Avslutad studie (Faktisk)
Studieregistreringsdatum
Först inskickad
Först inskickad som uppfyllde QC-kriterierna
Första postat (Uppskatta)
Uppdateringar av studier
Senaste uppdatering publicerad (Uppskatta)
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
Senast verifierad
Mer information
Termer relaterade till denna studie
Ytterligare relevanta MeSH-villkor
Andra studie-ID-nummer
- CV185-377
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .
Kliniska prövningar på Antikoagulation
-
Baxter Healthcare CorporationAvslutadAkut njurskada | Regional Citrate Anticoagulation (RCA) | Kontinuerlig njurersättningsterapi (CRRT)Förenta staterna, Kanada
-
Baxter Healthcare CorporationRekryteringRegional Citrate Anticoagulation (RCA) | Kontinuerlig njurersättningsterapi (CRRT) | Akut njurskada (AKI)Förenta staterna